Margriet Van Houtte

1000 total citations
20 papers, 839 citations indexed

About

Margriet Van Houtte is a scholar working on Virology, Infectious Diseases and Molecular Biology. According to data from OpenAlex, Margriet Van Houtte has authored 20 papers receiving a total of 839 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Virology, 19 papers in Infectious Diseases and 5 papers in Molecular Biology. Recurrent topics in Margriet Van Houtte's work include HIV Research and Treatment (20 papers), HIV/AIDS drug development and treatment (19 papers) and HIV/AIDS Research and Interventions (10 papers). Margriet Van Houtte is often cited by papers focused on HIV Research and Treatment (20 papers), HIV/AIDS drug development and treatment (19 papers) and HIV/AIDS Research and Interventions (10 papers). Margriet Van Houtte collaborates with scholars based in Germany, United Kingdom and United States. Margriet Van Houtte's co-authors include Stuart Bloor, Brendan Larder, Kurt Hertogs, Christel Van den Eynde, Veronica Miller, Rudi Pauwels, Sharon D. Kemp, Schlomo Staszewski, Timothy M. Alcorn and Marcus A. Conant and has published in prestigious journals such as PLoS ONE, Antimicrobial Agents and Chemotherapy and BMC Bioinformatics.

In The Last Decade

Margriet Van Houtte

17 papers receiving 796 citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Margriet Van Houtte 797 784 111 67 48 20 839
Christel Van den Eynde 640 0.8× 592 0.8× 79 0.7× 126 1.9× 120 2.5× 13 764
Elke Van Craenenbroeck 377 0.5× 348 0.4× 110 1.0× 55 0.8× 22 0.5× 11 461
Helen Scarnati 444 0.6× 434 0.6× 68 0.6× 56 0.8× 41 0.9× 12 518
Axel Fun 302 0.4× 287 0.4× 65 0.6× 56 0.8× 25 0.5× 15 391
Gabrielle Heilek‐Snyder 304 0.4× 316 0.4× 53 0.5× 44 0.7× 34 0.7× 7 351
Said Hassounah 405 0.5× 317 0.4× 172 1.5× 74 1.1× 17 0.4× 23 493
Marcia Van Ginderen 336 0.4× 284 0.4× 135 1.2× 109 1.6× 18 0.4× 6 387
Rujuta A. Bam 471 0.6× 379 0.5× 141 1.3× 135 2.0× 66 1.4× 11 609
Richard T. D'Aquila 867 1.1× 829 1.1× 56 0.5× 118 1.8× 54 1.1× 8 929
Kabamba Kabeya 438 0.5× 397 0.5× 101 0.9× 135 2.0× 73 1.5× 23 638

Countries citing papers authored by Margriet Van Houtte

Since Specialization
Citations

This map shows the geographic impact of Margriet Van Houtte's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Margriet Van Houtte with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Margriet Van Houtte more than expected).

Fields of papers citing papers by Margriet Van Houtte

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Margriet Van Houtte. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Margriet Van Houtte. The network helps show where Margriet Van Houtte may publish in the future.

Co-authorship network of co-authors of Margriet Van Houtte

This figure shows the co-authorship network connecting the top 25 collaborators of Margriet Van Houtte. A scholar is included among the top collaborators of Margriet Van Houtte based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Margriet Van Houtte. Margriet Van Houtte is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Steegen, Kim, Carole L. Wallis, Hans Wolf, et al.. (2012). HIV-1 Phenotypic Reverse Transcriptase Inhibitor Drug Resistance Test Interpretation Is Not Dependent on the Subtype of the Virus Backbone. PLoS ONE. 7(4). e34708–e34708. 7 indexed citations
2.
Garrido, Carmen, Jorge Villacian, Natalia Zahonero, et al.. (2012). Broad Phenotypic Cross-Resistance to Elvitegravir in HIV-Infected Patients Failing on Raltegravir-Containing Regimens. Antimicrobial Agents and Chemotherapy. 56(6). 2873–2878. 56 indexed citations
3.
Buzón, María J., Itziar Erkizia, Christian Pou, et al.. (2011). A non-infectious cell-based phenotypic assay for the assessment of HIV-1 susceptibility to protease inhibitors. Journal of Antimicrobial Chemotherapy. 67(1). 32–38. 6 indexed citations
4.
Malet, Isabelle, Slim Fourati, Charlotte Charpentier, et al.. (2011). The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype. Journal of Antimicrobial Chemotherapy. 66(12). 2827–2830. 36 indexed citations
5.
Borght, Koen Van der, Elke Van Craenenbroeck, Pierre Lecocq, et al.. (2011). Cross-validated stepwise regression for identification of novel non-nucleoside reverse transcriptase inhibitor resistance associated mutations. BMC Bioinformatics. 12(1). 386–386. 16 indexed citations
6.
Nauwelaers, David, Margriet Van Houtte, Kim Steegen, et al.. (2011). A Synthetic HIV-1 Subtype C Backbone Generates Comparable PR and RT Resistance Profiles to a Subtype B Backbone in a Recombinant Virus Assay. PLoS ONE. 6(5). e19643–e19643. 4 indexed citations
7.
Dunn, David, Ruth Goodall, Paula Munderi, et al.. (2011). Residual Activity of Two HIV Antiretroviral Regimens Prescribed without Virological Monitoring. Antimicrobial Agents and Chemotherapy. 55(10). 4575–4580.
8.
Stürmer, Martin, Christoph Stephan, Peter Gute, et al.. (2011). Comparison of Drug Resistance Scores for Tipranavir in Protease Inhibitor-Naïve Patients Infected with HIV-1 B and Non-B Subtypes. Antimicrobial Agents and Chemotherapy. 55(11). 5362–5366. 4 indexed citations
9.
Houtte, Margriet Van, Gastón Picchio, Koen Van der Borght, et al.. (2009). A comparison of HIV‐1 drug susceptibility as provided by conventional phenotyping and by a phenotype prediction tool based on viral genotype. Journal of Medical Virology. 81(10). 1702–1709. 25 indexed citations
10.
Muyldermans, Gaëtan, et al.. (2008). Reproducibility of a high-throughput HIV-1 genotypic resistance assay over time (2001–2007). Journal of the International AIDS Society. 11(Suppl 1). P205–P205. 1 indexed citations
11.
Muyldermans, Gaëtan, et al.. (2008). Reduced susceptibility to lamivudine and emtricitabine associated with the novel K66N mutation in HIV-1 reverse transcriptase. Journal of the International AIDS Society. 11(Suppl 1). P187–P187. 1 indexed citations
12.
Bradshaw, Daniel, Shazia Malik, Clare Booth, et al.. (2007). Novel Drug Resistance Pattern Associated with the Mutations K70G and M184V in Human Immunodeficiency Virus Type 1 Reverse Transcriptase. Antimicrobial Agents and Chemotherapy. 51(12). 4489–4491. 10 indexed citations
13.
Houtte, Margriet Van, et al.. (2006). NRTI resistance associated with the RT mutation K70E in HIV-1. Antiviral Therapy. 11(5). 3 indexed citations
14.
Vergne, Laurence, Lieven Stuyver, Margriet Van Houtte, et al.. (2006). Natural polymorphism in protease and reverse transcriptase genes and in vitro antiretroviral drug susceptibilities of non-B HIV-1 strains from treatment-naive patients. Journal of Clinical Virology. 36(1). 43–49. 53 indexed citations
15.
Vermeiren, Hans, Tim Van den Bulcke, Herwig Van Marck, et al.. (2004). Application of multiple linear regression modelling to the quantitative prediction of HIV-1 drug susceptibility phenotype from viral genotype. Antiviral Therapy. 9(4). 2 indexed citations
16.
Marck, Herwig Van, Tim Van den Bulcke, Margriet Van Houtte, Pierre Lecocq, & Lee T. Bacheler. (2003). Quantitative prediction of HIV drug susceptibility from viral genotype through linear regression modelling. Antiviral Therapy. 8(3). 2 indexed citations
17.
Verbiest, Werner, Stephen Brown, Calvin Cohen, et al.. (2001). Prevalence of HIV-1 drug resistance in antiretroviral-naive patients: a prospective study. AIDS. 15(5). 647–650. 16 indexed citations
18.
Hertogs, Kurt, Stuart Bloor, Sharon D. Kemp, et al.. (2000). Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples. AIDS. 14(9). 1203–1210. 157 indexed citations
19.
Hertogs, Kurt, Stuart Bloor, Véronique De Vroey, et al.. (2000). A Novel Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutational Pattern Confers Phenotypic Lamivudine Resistance in the Absence of Mutation 184V. Antimicrobial Agents and Chemotherapy. 44(3). 568–573. 102 indexed citations
20.
Hertogs, Kurt, Marie‐Pierre de Béthune, Veronica Miller, et al.. (1998). A Rapid Method for Simultaneous Detection of Phenotypic Resistance to Inhibitors of Protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1 Isolates from Patients Treated with Antiretroviral Drugs. Antimicrobial Agents and Chemotherapy. 42(2). 269–276. 338 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christel Van den Eynde Breakdown of academic impact, for papers by Elke Van Craenenbroeck Breakdown of academic impact, for papers by Helen Scarnati Breakdown of academic impact, for papers by Axel Fun Breakdown of academic impact, for papers by Gabrielle Heilek‐Snyder Breakdown of academic impact, for papers by Said Hassounah Breakdown of academic impact, for papers by Marcia Van Ginderen Breakdown of academic impact, for papers by Rujuta A. Bam Breakdown of academic impact, for papers by Richard T. D'Aquila Breakdown of academic impact, for papers by Kabamba Kabeya
Rankless by CCL
2026